Valeant Pharmaceuticals International, Inc. (NYSE:VRX) could surge as high as $175

8571

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has a 1 Year Target Estimate of $43.63. The stock traded with the volume of 7.76 Million in the last trading session. Valeant Pharmaceuticals International, Inc. opened at $26.12 and closed at $26.28 by showing an increase of 0.53%. The Bid price in the last session was $26.07 x 300 and the Ask price was $26.74 x 300. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).

Valeant Pharmaceuticals International, Inc. has the Market Capitalization of 9.18 Billion. The Stock has its 52-week High of $182.64 and 52-Week Low of $18.55 and it touched its 52-week high on Oct 2, 2015 and 52-Week Low on Jun 27, 2016.

Valeant Pharmaceuticals International, Inc. reported its last Earnings on Aug 09 BMO where the company reported Actual EPS of $1.4/Share whereas, the Analyst Estimated EPS was $1.47/share. The difference between Actual EPS and Estimated EPS was $-0.07/share. This represented an Earnings Surprise of -4.8%.

Some analyst provided their insight on Growth Estimates; Valeant Pharmaceuticals International, Inc. has the Current Quarter Earnings Growth rate of -35%. The Next Quarter growth is expected to be -17.6%. In the past 5 years, the stock has earnings growth rate of 24.31% per annum while the Upcoming 5 year’s earnings growth rate is expected to be 6.5% per annum.

19 number of analysts also provided their insight on Valeant Pharmaceuticals International, Inc., where the Average Price Target for the stock is $43.63. They also projected Low Price Target as $16 while High Price Target is set at $175.

A number of analysts rated the stock as well: 1 analysts believe that the stock is a STRONG BUY while 0 reported it as Buy.5 analysts assigned a HOLD rating, 1 said it’s UNDERPERFORM and 0 say that this stock is a SELL.

Valeant Pharmaceuticals International, Inc. annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 0 and Forward Price to Earnings ratio of 3.43. The company has its Price to Sales (P/S) ratio of 0.87 where Price to Book (P/B) ratio of 1.72, Price to Cash Per share (P/C) of 10.59 and Price to Free Cash Flow (P/FCF) has a value of 6.93.

The company has its Return on Assets (ROA) of -2 Percent. Return on Equity (ROE) stands at -17% and Return on Investment (ROI) displays a value of 3.7%.

The stock is currently trading at Distance from 20-Day simple moving Average of -5.68% whereas, Distance from 50-Day Simple moving average is -0.88 Percent and Distance from 200-Day Simple Moving Average of -43.77 percent.

A look at performance overview of Valeant Pharmaceuticals International, Inc. depicts that Performance (Week) is -2.04 percent while Performance Month is -12.66%. Quarterly performance shows a value of 30.34% and Half Year Performance value stands at 0.46%. Yearly performance of the stock has the value of -83.29 percent. Valeant Pharmaceuticals International, Inc. has its YTD performance of -74.01 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).

Upgrades/Downgrades Report:

The latest Upgrades/Downgrades was done by Research firm Morgan Stanley on 17-Aug-16 who Upgrade the stock from Equal-Weight to Overweight. Other firms have also Upgraded/Downgraded the stock. On 15-Aug-16, Mizuho took an action “Upgrade” from Underperform to Neutral. On 23-Jun-16, the stock was Downgrade to Neutral by JP Morgan.

SHARE